BiomedReports: News and FDA Updates for Orexigen (Nasdaq:OREX), Shire (NASDAQ ... Trading Markets (press release) ... lisdexamfetamine dimesylate-currently marketed by Shire US Inc. for the treatment of attention-deficit hyperactivity disorder under the name VYVANSE(R). ... and more » |
News and FDA Updates for Orexigen® (Nasdaq:OREX), Shire (NASDAQ:SHPGY) American Chronicle ... lisdexamfetamine dimesylate-currently marketed by Shire US Inc. for the treatment of attention-deficit hyperactivity disorder under the name VYVANSE(R). and more » |

